TSE:4523Pharmaceuticals
Do Eisai’s (TSE:4523) Rising Sales but Softer Profits Reframe Its Alzheimer’s Investment Story?
In February 2026, Eisai Co., Ltd. held a board meeting to consider the appointment of corporate officers and reported nine-month results to December 31, 2025, with sales of ¥619,950 million and net income of ¥41,808 million.
The combination of higher sales yet lower net income and earnings per share than a year earlier highlights rising cost or mix pressures that may concern investors evaluating Eisai’s profitability profile.
Next, we’ll explore how Eisai’s higher sales but lower nine-month...